Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.
Full article >>
Wednesday, April 29, 2009
Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment